Minervini Andrea, Di Cristofano Claudio, Gacci Mauro, Serni Sergio, Menicagli Michele, Lanciotti Michele, Salinitri Giuseppe, Rocca Carlo Della, Lapini Alberto, Nesi Gabriella, Bevilacqua Generoso, Minervini Riccardo, Carini Marco
Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
J Urol. 2008 Oct;180(4):1284-9. doi: 10.1016/j.juro.2008.06.036. Epub 2008 Aug 15.
We defined the prognostic role of tumor necrosis and its extent in nonmetastatic clear cell renal cell carcinoma. Also, we further investigated its pathogenesis by correlating this tumor feature with other pathological characteristics and molecular markers related to the von Hippel Lindau-hypoxia inducible factor pathway and to tumor proliferation.
A total of 213 patients with nonmetastatic clear cell renal cell carcinoma were evaluated. Mean followup was 66 months. The presence and extent of histological necrosis were correlated with clinicopathological factors, Ki-67 antigen expression calculated by the MIB-1 (Ki-67 antibody) index, pVHL, HIF-1alpha, the tumor infiltrating lymphocyte subset and cancer specific survival.
Histological necrosis was present in 63.8% of clear cell renal cell carcinoma cases. Necrosis was significantly associated with grade and the degree of tumor infiltrating lymphocytes, while its extent correlated significantly with grade, the degree of tumor infiltrating lymphocytes and stage. Tumor necrosis was a significant prognostic factor, which was confirmed even when limiting analysis to patients with intracapsular renal cell carcinoma. On multivariate analysis histological necrosis was not an independent predictor of cancer specific survival. The extent of tumor necrosis was not a significant prognostic factor. The presence and extent of histological necrosis was not associated with high Ki-67 expression and it did not correlate with pVHL expression or with nuclear and cytoplasmic HIF-1alpha expression.
Based on our results we cannot support histological necrosis and its extent as prognostic factors for clear cell renal cell carcinoma. Efforts should be made to develop nomograms that use routinely available and objective predictor variables. The precise mechanism that causes tumor necrosis remains unknown but the host immune response might significantly contribute to its development.
我们明确了肿瘤坏死及其范围在非转移性透明细胞肾细胞癌中的预后作用。此外,我们通过将这一肿瘤特征与其他病理特征以及与冯·希佩尔-林道-缺氧诱导因子途径和肿瘤增殖相关的分子标志物进行关联,进一步研究了其发病机制。
共评估了213例非转移性透明细胞肾细胞癌患者。平均随访时间为66个月。组织学坏死的存在和范围与临床病理因素、通过MIB-1(Ki-67抗体)指数计算的Ki-67抗原表达、pVHL、HIF-1α、肿瘤浸润淋巴细胞亚群和癌症特异性生存相关。
63.8%的透明细胞肾细胞癌病例存在组织学坏死。坏死与分级和肿瘤浸润淋巴细胞程度显著相关,而其范围与分级、肿瘤浸润淋巴细胞程度和分期显著相关。肿瘤坏死是一个显著的预后因素,即使将分析局限于肾包膜内肾细胞癌患者时也得到了证实。多因素分析显示,组织学坏死不是癌症特异性生存的独立预测因素。肿瘤坏死范围不是一个显著的预后因素。组织学坏死的存在和范围与高Ki-67表达无关,也与pVHL表达或核及胞质HIF-1α表达无关。
基于我们的结果,我们不支持将组织学坏死及其范围作为透明细胞肾细胞癌的预后因素。应努力开发使用常规可用且客观预测变量的列线图。导致肿瘤坏死的确切机制尚不清楚,但宿主免疫反应可能对其发展有显著贡献。